Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration has approved Tesaro’s Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.
Alexion Pharmaceuticals’s Board of Directors has appointed Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the Board of Directors, to succeed David R. Brennan, who has led the company as Interim CEO since December 2016.
PureTech Health said on Friday that it will advance with Novartis two clinical-stage programmes targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway.
EMD Serono, U.S. company focused on specialty care has received U.S. Food and Drug Administration (FDA) approval for its rare skin cancer drug.
Latino population in the United States of America have higher rates of cardio-metabolic diseases than in rest of the population, said David Kerr, director of Innovation and Research for the William Sansum Diabetes center.
A major research has been initiated, which will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.
Alcon, a division of Novartis, has received approval from the US Food and Drug Administration (FDA) for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens (IOL) with Activefocus optical design for patients undergoing cataract surgery who choose to address their astigmatism and presbyopia at the same time.
The U.S. Food and Drug Administration has approved Newron Pharmaceuticals’s Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa.
Galapagos NV has reached a milestone in a Phase 1 study for cystic fibrosis, it is conducting with its partner AbbVie, …
Kaya Holdings got its third Marijuana Retailer license from the Oregon Liquor Control Commission (OLCC), and has opened its third Kaya Shack Retail Marijuana location.